Pfizer Picks Up Fort Dodge Equine Products through Merger
Clint Lewis, president of U.S. Operations for Pfizer and responsible for the entire U.S. division of Pfizer Animal Health, told TheHorse.com Oct. 21 that the merger of Pfizer with Wyeth (including Fort Dodge Animal Health) resulted in a company “with a strong commitment to the horse.
“No other company will be as committed to having new tools and resources for veterinarians and horse
- Topics: Article
Clint Lewis, president of U.S. Operations for Pfizer and responsible for the entire U.S. division of Pfizer Animal Health, told TheHorse.com Oct. 21 that the merger of Pfizer with Wyeth (including Fort Dodge Animal Health) resulted in a company “with a strong commitment to the horse.
“No other company will be as committed to having new tools and resources for veterinarians and horse owners,” Lewis said.
Lewis said the only three products that were divested were Pfizer’s Equell, Equimax, and Rhinomune. As of Sept. 30, 2009, the marketing rights for Equell (ivermectin) paste and Equimax (ivermectin/praziquantel) paste in the United States and Canada were transferred exclusively to Bimeda Inc and Bimeda MTC Animal Health, according to Pfizer.
The remainder of the Fort Dodge Animal Health equine line of products was married with the Pfizer line of products, he added
Create a free account with TheHorse.com to view this content.
TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.
Start your free account today!
Already have an account?
and continue reading.

Related Articles
Stay on top of the most recent Horse Health news with